ERBB2 and breast cancer: The presence of ductal carcinoma in situ (DCIS) adjacent to IBC, observed in 57–72% of HER2-positive breast cancer patients, may, however, impede this de-escalation of surgery, as DCIS is considered insensitive to systemic treatment [10–17].